European regulators green-light a host of new drugs

There was a lineup of important European drug decisions released today. At the top of the list:

European regulators have given a green light to Glaxosmithkline's OTC version of the obesity drug Xenical.

- check out the report from The Scotsman

ALSO: France's Ipsen announced that the CHMP recommended marketing authorization for Increlex. A formal approval will trigger a $20 million milestone payment to Tercica. Release

> European regulators are recommending the use of Sanofi-Aventis' Plavix for stent patients. Report

> Roche's anemia drug Mircera got a thumb's up from European regulators as well. The therapy has been delayed in the U.S. as the FDA ponders the fate of anemia drugs in the face of new safety data. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.